Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.
Leora Horn, MD, MSc
Advertisement
Articles by Leora Horn, MD, MSc
Advertisement
Latest Updated Articles
- Immune Checkpoint Inhibition in Lung Cancer: The Good, the Bad, and the Ugly
Published: August 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers
2
ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors
3
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma
4
Debate Round 3: Timing of Treatment Initiation in LR-MDS (Earlier vs Delayed)
5
